Genentech Newswire

Comprehensive Real-Time News Feed for Genentech.

Results 1 - 20 of 524 in Genentech

  1. Swiss drug maker Roche posts 7 percent profit dropRead the original story w/Photo

    3 hrs ago | Washington Examiner

    ... Perjeta and Kadcyla, and by its diagnostics products. This month, Roche said its U.S.-based biotech company Genentech had agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.73 billion in cash and contingency ...

    Comment?

  2. Community Impact: bringing students face to face with the world's top scientistsRead the original story w/Photo

    6 hrs ago | Business Journal

    What better way to get students interested in science than to bring them into one of the top biotechs in the world? Genentech's Gene Academy shuttles students from three South San Francisco elementary schools and one middle school to the Genentech campus once a week for help with homework and projects as well as to talk with scientists at their ... (more)

    Comment?

  3. Advanced Biological Laboratories (ABL) and Roche Diagnostics...Read the original story

    9 hrs ago | Business Wire

    ... 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai ...

    Comment?

  4. Cypher Genomics Appoints to the Board of Directors, Henry Nordhoff as ...Read the original story

    10 hrs ago | Freshnews

    ... board of directors. In addition, Cypher appointed as directors: Herbert Boyer, Ph.D. , who co-founded and led Genentech as vice president, and Andrew von Eschenbach, M.D. , who was the former commissioner of the U.S. Food and Drug Administration ...

    Comment?

  5. Roche Profit Dented by CurrenciesRead the original story w/Photo

    13 hrs ago | Wall Street Journal

    Roche Holding AG reported Thursday that first-half net profit slid 7% under pressure from exchange rates, but strong sales of its cancer therapies prompted the Swiss drug giant to confirm its outlook for the full year.

    Comment?

  6. Roche Profit Falls on Franc Strengthl New-Drug Sales RiseRead the original story

    14 hrs ago | Bloomberg

    Roche Holding AG 's first-half profit fell 7 percent as the strength of the Swiss franc offset rising sales of the drugmaker's new cancer medicines.

    Comment?

  7. Ottawa cancer lab part of 'stepping into this future,' newly recruited director saysRead the original story w/Photo

    Tuesday | Ottawa Citizen

    ... he has trained at Toronto's Hospital for Sick Children, then at Yale University, and recently worked at Genentech Inc. in California. "It's of course really exciting to be a part of something brand new. This lab is going to be put together from the ...

    Comment?

  8. Asthma drug may help those with chronic hivesRead the original story w/Photo

    Tuesday | WJRT

    ... for more than six weeks," explained study senior author Dr. Karin Rosen, an associate group medical director with Genentech Inc., in San Francisco. "That's usually just .5 to 1 percent of hives patients." "But for those patients, this is a really ...

    Comment?

  9. New Market Study, "Follicular Lymphoma - Pipeline Review, H2 2014", Has Been PublishedRead the original story

    Tuesday | SBWire

    ... Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Amgen Inc., GlaxoSmithKline plc, Genentech, Inc., MedImmune, LLC, Gilead Sciences, Inc., Merck & Co., Inc., Infinity Pharmaceuticals, Inc., Celltrion, Inc., Millennium ...

    Comment?

  10. Donaco International Limited (ASX:DNA) On-Market Buy-Back and Appendix 3CRead the original story

    Monday | Hispanic Business

    The buy-back is being undertaken as part of the Company's ongoing capital management program.

    Comment?

  11. Asthma Drug Found Effective Against Chronic HivesRead the original story

    Monday Jul 21 | News Max

    ... for more than six weeks," explained study senior author Dr. Karin Rosen, an associate group medical director with Genentech Inc., in San Francisco. "That's usually just .5 to 1 percent of hives patients." "But for those patients, this is a really ...

    Comment?

  12. Genentech Alzheimer's drug misses goals in studiesRead the original story

    Friday Jul 18 | WTVF Nashville

    An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.

    Comment?

  13. Now Available: Allergic Asthma - Pipeline Review, H1 2014Read the original story

    Friday Jul 18 | SBWire

    ... drove them from pipeline Companies Mentioned in this Report: Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Genentech, Inc., BioTech Tools, Dainippon Sumitomo Pharma Co., Ltd., Infinity Pharmaceuticals, Inc., Novartis AG, ALK-Abello A/S, DBV ...

    Comment?

  14. Genentech Alzheimer's drug misses study goals but shows some promise in milder diseaseRead the original story w/Photo

    Thursday Jul 17 | Canada.com

    ... of a brain damaged by advanced Alzheimer's disease. Researchers said an experimental drug from the biotech company Genentech failed to slow mental decline in tests on more than 500 people with mild to moderate Alzheimer's disease. An experimental ...

    Comment?

  15. Genentech Alzheimera s drug misses goals in studiesRead the original story

    Wednesday Jul 16 | KDWN

    An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.

    Comment?

  16. Genentech Alzheimer's drug crashes in clinical trial a maybeRead the original story w/Photo

    Wednesday Jul 16 | Business Journal

    Genentech must decide if data from a mid-stage Alzheimer's disease drug trial is promising enough to pursue another study in patients with a mild form of the disease.

    Comment?

  17. Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014Read the original story

    Wednesday Jul 16 | Business Wire

    ... Exelixis-discovered compound, cobimetinib, a highly selective inhibitor of MEK, is being evaluated by Roche and Genentech, Inc. (a member of the Roche Group) in a broad development program under a collaboration with Exelixis. For more information, ...

    Comment?

  18. Recent Findings from Genentech, Inc. Provides New Insights into...Read the original story

    Wednesday Jul 16 | Hispanic Business

    Small-scale studies performed at the 2 L scale consistently showed an increase in acidic species when compared with the material made at larger scale."

    Comment?

  19. Alzheimer's Drug Fails to Help Moderately Ill in TrialsRead the original story

    Wednesday Jul 16 | Bloomberg

    ... to develop the disease in their 40s because of a gene mutation. That study is sponsored by Roche's U.S.-based Genentech unit and the Banner Alzheimer's Institute. Novartis AG (NOVN) , Roche's cross-town rival in Basel, also announced yesterday it ...

    Comment?

  20. Genentech Alzheimera s drug misses goals in studiesRead the original story

    Wednesday Jul 16 | KDWN

    An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.

    Comment?